VolitionRx reports Q2 revenue $396K, consensus $480K

CEO Cameron Reynolds said: “So far this year we have successfully supported our veterinary licensing and distribution partners to launch our Nu.Q Vet Cancer test and I am delighted that we have sold more tests in the first half of 2024 than the whole of 2023. We have also made significant progress in readying our Nu.Q NETs product for sepsis, Nu.Q Lung Cancer and Capture-PCR technologies for licensing. We have a large amount of study data that we expect is close to being ready for inclusion in the data rooms and we have received expressions of interest from key industry players. Our focus in the second half of 2024 will include negotiating our first licensing deal in the human space and to that end, PharmaVentures, a respected, international advisory company with a proven track record, has recently been engaged to act as an advisor to Volition to help secure licensing deals for both Nu.Q Cancer and Capture-PCR.”